CoChat

Pharmacokinetics and tolerability of SRT 2104, a first‐in‐class small molecule activator of SIRT 1, after single and repeated oral administration in man

Open access
Hoffmann, Ethan, Wald, Jeff, Lavu, Siva, Roberts, John, Beaumont, Claire, Haddad, Jon, Elliott, Peter, Westphal, Christoph, Jacobson, Eric · 2013 · British Journal of Clinical Pharmacology
Cited by 132

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Aim: SRT 2104 is a novel, first‐in‐class, highly selective small molecule activator of the NAD + dependent deacetylase SIRT 1. SRT 2104 was dosed to healthy male and female volunteers in a series of phase 1 clinical studies that were designed to elucidate tolerability and pharmacokinetics associated with oral dosing to aid in dose selection for subsequent clinical trials. Methods: In the first‐in‐human study, there was both a single dose phase and 7 day repeat dose phase. Doses used ranged from 0.03 to 3.0 g. A radioactive microtracer study was subsequently conducted to determine systemic clearance, bioavailability and preliminary metabolism, and a crossover study was conducted to determine the effect of gender, formulation and feeding state on SRT 2104 pharmacokinetics. Results: SRT 2104 was well tolerated in all of these studies, with no serious adverse reactions observed. SRT 2104 displayed a dose‐dependent, but sub‐proportional increase in exposure following single dose and repeated dose administration. Accumulation of three‐fold or less occurs after 7 days of repeat dosing. The mean bioavailability was circa 14% and the mean clearance was circa 400 ml min−1. Although there were no substantial effects on exposure resulting from gender or formulation differences, a notable food effect was observed, manifested as up to four‐fold increase in exposure parameters. Conclusions: In the absence of an optimized formulation of SRT 2104, the food effect can be used to maximize exposure in future clinical studies. Combined with the good tolerability of all doses demonstrated in these studies, the favourable selectivity profile of SRT 2104 allows for the use of this SIRT 1 modulator for target validation in the clinic.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2012.04340.x

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 132

Metadata

Authors
Hoffmann, E., Wald, J., Lavu, S., Roberts, J., Beaumont, C., Haddad, J., Elliott, P., Westphal, C., & Jacobson, E.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2012-12-14
Volume
75
Issue
1
Pages
186-196
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1736016875
Cited by
132
References
19
FWCI
5.73
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.